The cobas EGFR Mutation Test (v1) was FDA-approved on May 14, 2013 for the qualitative detection of exon 19 deletions and exon 21 (p.(Leu858Arg)) substitution mutations of the EGFR gene in DNA derived from FFPE human NSCLC tumor tissue [17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.